Abridge Funding History
Abridge develops AI software that turns conversations between clinicians and patients into structured medical documentation. It serves health systems, focusing on clinical notes and the documentation workflow surrounding patient visits.
Company Overview
Abridge Funding Timeline
Abridge’s financing announcements trace its move from clinical documentation into coding and reimbursement workflows.
Series E
$300M · $5.3B valuation
Abridge said it would use the capital to bring coding and reimbursement workflows closer to the clinical encounter, building on its existing documentation tools.
Led by Andreessen Horowitz. Participation included Khosla Ventures.
Source · abridge.com ↗Series D
US$250 million
Abridge raised this round as it expanded its clinical documentation platform across health systems and developed tools for a wider range of care settings.
Led by Elad Gil, IVP. Participation included Bessemer, CapitalG and 6 more on record.
Source · abridge.com ↗Series C
US$150 million
The round followed the Series B by four months. Abridge said the additional capital would accelerate research and development as more health systems adopted the product.
Led by Lightspeed Venture Partners, Redpoint. Participation included IVP, Spark Capital and 2 more on record.
Source · abridge.com ↗Series B
US$30 million
Abridge raised the round to bring its clinical documentation software to more US health systems, expanding adoption beyond its early deployments.
Led by Spark Capital. Participation included Bessemer, CVS Health Ventures, Mayo Clinic Ventures.
Source · abridge.com ↗Series A-1
$12.5M
Abridge launched its enterprise documentation product alongside the round. It said the capital would grow its team and fund research into automating clinical documentation.
Led by Wittington Ventures. Participation included Union Square Ventures, Bessemer, Pillar Venture Capital and 3 more on record.
Source · abridge.com ↗
FAQ
How do ambient clinical notes differ from a visit transcript?
A transcript records speech. A clinical note organizes the encounter into documentation used by care teams. Clinicians still need to review the output for accuracy and omissions.
Does funding establish that an AI scribe is clinically safe?
No. Financing does not substitute for clinical validation, privacy review or evaluation in a specific health system.
Why do health-system integrations matter for documentation software?
A useful note must fit existing review and electronic health record workflows. Deployment work can therefore matter alongside the underlying speech and language models.
Does Abridge’s Series E amount equal its lifetime funding?
The selected Series E is one financing event. Its amount must not be presented as the sum of all earlier rounds.
Why can an announcement omit a valuation that reporting supplies?
Companies can announce a financing without publishing every term. Read the linked source to distinguish company-disclosed terms from a valuation attributed to reporting.
What should clinicians assess beyond an ambient AI vendor’s investors?
Evaluate note quality, specialty coverage, consent processes, data handling and the burden of correcting errors in the actual clinical workflow.